AAI101, a Novel β-Lactamase Inhibitor: Microbiological and Enzymatic Profiling

نویسندگان

  • Krisztina M Papp-Wallace
  • Christopher R Bethel
  • Melissa D Barnes
  • Joseph D Rutter
  • Magdalena A Taracila
  • Saralee Bajaksouzian
  • Michael R Jacobs
  • Robert A Bonomo
چکیده

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

In Vitro Activity of Cefepime/AAI101 and Comparators against Cefepime Non-susceptible Enterobacteriaceae

We evaluated the in vitro potency of cefepime combined with AAI101, a novel extended-spectrum β-lactamase inhibitor, against a population of clinical Escherichia coli and Klebsiella pneumoniae collected from USA hospitals. Of the 223 cefepime non-susceptible isolates, 95% were ceftazidime non-susceptible, 49% ertapenem non-susceptible, 57% piperacillin/tazobactam non-susceptible, 90% were multi...

متن کامل

In vivo activities of simulated human doses of cefepime and cefepime-AAI101 against multidrug-resistant Gram-negative Enterobacteriaceae.

The combination of cefepime with AAI101, a novel extended-spectrum β-lactamase inhibitor, possesses potent in vitro activity against many resistant Gram-negative pathogens. Against a panel of 20 mostly carbapenemase-producing cefepime-nonsusceptible strains of the family Enterobacteriaceae, we evaluated the MICs of cefepime in the presence of various fixed AAI101 concentrations (1, 2, 4, 8, and...

متن کامل

Activity of the Novel Extended-spectrum β-Lactamase Inhibitor AAI101 in Combination with Cefepime Towards a Challenge Panel of Acinetobacter baumannii

1197. Frequency of Antimicrobial Resistance in Shiga Toxin-Producing Escherichia coli (STEC) and Non-Typhoidal Salmonella (NTS) Clinical Infections and Association with Epidemiological Factors Sanjana Mukherjee, MS; Rebekah Mosci, MS; Chase Anderson, -; Brian Snyder, BS; James Collins, MPH, RS; James Rudrik, PhD and Shannon D. Manning, PhD; Microbiology and Molecular Genetics, Michigan State Un...

متن کامل

The β-lactamase inhibitor avibactam (NXL104) does not induce ampC β-lactamase in Enterobacter cloacae

Induction of ampC β-lactamase expression can often compromise antibiotic treatment and is triggered by several β-lactams (such as cefoxitin and imipenem) and by the β-lactamase inhibitor clavulanic acid. The novel β-lactamase inhibitor avibactam (NXL104) is a potent inhibitor of both class A and class C enzymes. The potential of avibactam for induction of ampC expression in Enterobacter cloacae...

متن کامل

تعیین الگوی مقاومت ایزوله‌های بالینی اشریشیاکلی مولد بتالاکتامازهای وسیع‌الطیف نوع AmpC براساس خصوصیات فنوتیپی و ژنوتیپی

  Introduction : The widespread use of β -lactam antibiotic has lead to the development of resistance to this group of antibiotics in bacterial pathogens due to β -lactamase production. This study was undertaken to determine the AmpC β -lactamase production in pathogens isolated from hospitalized patients at selected university hospitals of Tehran.   Materials & Methods: Non-repeat clinical iso...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:

دوره 4  شماره 

صفحات  -

تاریخ انتشار 2017